UK pharma giant records net loss for the second quarter but is set to gain from export-driven growth. » Read More
Biotech stocks are some of Nasdaq's best performing this year. Joel Sendek, Stifel Nicolaus, looks at names leading the biotech boom.
How are biotech companies and the FDA impacted by the government shutdown? Yaron Werber of Citi Investment Research, offers insight.
Mad Money host Jim Cramer calls Array BioPharma a spec play. The company has 6 trials in phase 3 in progress. Its CEO Ron Squarer discusses its partnerships with big players including Novartis and Celgene.
Zac Vawter has been fitted with the first thought-controlled bionic leg, scientists at the Rehabilitation Institute of Chicago reported.
Want to avoid taking a hit on your portfolio because of troubles in Washington? Cramer found one sector that will be a shelter from the storm.
Amgen has struck a $10 billion-plus deal to buy Onyx Pharmaceuticals, ending a two-month-long auction for the cancer drugmaker.
Amgen is close to buying Onyx for $125 per share, or more than $10 billion, in a deal that is expected to be announced as soon as Monday, two people familiar with the matter said on Saturday.
CNBC's Seema Mody reports the biggest movers in the Nasdaq including Apple, and biotech stocks.
A judge ordered the American Quarter Horse Association to allow cloned horses to be entered into the breed's official registry, which could clear the way for the clones to race.
In an effort to clean up the image of genetically modified crops, major seed and crop science companies launched GMOAnswers.com to answer questions about so-called GMOs.
Biotech stocks are some of the best-performing S&P stocks this month. Chris Raymond, senior biotech analyst at Robert W. Baird, shares his top picks.
Health care stocks have been up almost across the board since 2010. Biotech and insurance names have been up triple digits. But political developments have put health care on a rockier path. CNBC's Kate Kelly breaks down the sector.
Genetically modified seeds are used in corn and soybeans grown in the US, but the debate over the effects of tinkering with Mother Nature hasn't gone away.
Independent of the debate on the Federal Reserve and interest rates, FTI Consulting's Barbara Ryan expects pharmaceutical and biotech stocks can continue to do well.
Last year $2 billion worth of products were sold with a label saying they do not contain ingredients from genetically modified organisms, but the claim wasn't backed by regulators.
Biotech and drug companies say the benefits of genome research are on the way, and just as importantly, advances are pushing the technology toward affordability.
Russian tycoon Dmitry Itskov is convening a meeting of the minds to explore the possibility of creating lifelike copies of humans, something he thinks is possible by 2035.
A strain of genetically engineered wheat never approved for sale or consumption was sprouting on a farm in Oregon, the Agriculture Department said Wednesday.
Shares of Pandora are up after the company reported earnings, reports CNBC's Seema Mody. And there are reports a deal between Valeant Pharmaceuticals and Bausch & Lomb could be completed as early as next week.
Following is Cramer's homework. And he's concerned about a few of the stocks he's just researched.